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Abstract. The purpose of this paper is to describe the role of non-integer models in healthcare
pathways and how these tools provide a breakthrough in our understanding of drug delivery
protocols. Two examples will be given as being typical of such applications: modeling glucose
levels in diabetic type I patients and modeling pain transmission in patients suffering from (post
operative) chronic pain. A wide range of tools to model these pathways and their role for use in
healthcare delivery for optimal treatment and patient well-being are discussed. Individualized
patient healthcare is nowadays top priority in European research framework for health and these
modeling tools are primary aids in meeting these challenges.
1. Introduction
Personalized healthcare is at todays research core. Specificity of drug titration and treatment for
the modern patient implies the availability, readiness of use and employment of novel tools and
concepts with a background in a deep-rooted, well established clinical and medical expertise.
Although as recognized still today, clinical practice is still an art rather than a science, efforts
are being channeled to move from state of use to state of art. As such, state of art is far more
advanced, but it lacks suitable platforms for integration, the so called cyber-physical systems,
demanding hybrid sources of information processing, filtering, securing and translating into
usable variables and meaningful values. A critical role of this personalized healthcare wave
in current trends of research is given to the patient itself, with all its specificity, as observed
from figure 1. Specificity demands the availability of individualized models, for prediction of
drug effects and for steering the optimal drug titration and treatment to the patient. The goal
of this paper is to bring forward the latest trends in modeling for individualized healthcare
purposes. A review of state of art and state of use will be given, along with suggestions for
further developments and remaining challenges.
The model is some formalized representation of the input-output relationship; mostly a
mathematical model. The model will in general depend on certain parameters, such as body
weight of the patient, clearance of the administered drug, etc. The adaptor is a tool to adapt
the initial estimates of the parameters, whereby the controller transforms the error signal in
commands for dosing. The core of feedback systems is a model of the patient with respect to
the relationship between drug dosing and drug effect. Such models can be used in two directions.
Using the feedforward direction it can give a prediction of the measured output. In the backwards
Figure 1. Block diagram of a generic model-based adaptive closed-loop system for automatic
drug delivery. The closed-loop system consists of five parts: the patient, as the system to be
controlled; the response that is considered as a measurable representation of the process to be
controlled; a model of the inputoutput relationship, for instance a mathematical formula; and a
controller, which transforms the error signal and the set-point to a drug delivery scheme
direction it can be used to determine the necessary input to achieve and maintain a certain level
of the output. The paper will present two applications of such drug delivery systems: anesthesia
and diabetes type I.
2. State of use
Pharmacokinetics describes the relationship between drug dose and drug concentration in plasma
or the effect site. This relationship is described by processes of absorption, distribution and
clearance. Notice that for intravenous drugs (e.g. anesthesia), absorption is irrelevant, so
pharmacokinetic properties are described by distribution and clearance alone [1, 2].
We summarize two types of pharmacokinetic models, with prevalence for the most commonly
used compartmental model. These models offer a tool for understanding the relationship between
pharmacokinetics and cardiovascular physiology. The physiologic estimates are usually less
accurate than fully-described physiologic models, but they represent the actual pharmacokinetics
and delineate the basis for changed states of intravenous pharmacokinetics. To our knowledge,
these concepts denote the inter-patient variability and intra-patient variability, which is in fact
the challenging problem for optimal drug dosing [3, 4]. In principle, the altered physiological
states mark a significant departure from the expected dose-response relationship, hence marked
variations. Drug elimination is related to the efficiency of metabolism and/or excretion carried
out by the organs of the drug elimination (e.g. liver, kidney, lung), as well as the blood
flow to these organs. The two basic approaches for analyzing the effects of physiology on
pharmacokinetics are the so-called forward and inverse models. With the forward model or
problem, investigators estimate or measure the blood flow to each of the major organs (e.g.
lungs, heart, brain, kidneys, liver, intestines) and tissue types (e.g. muscle, fat, skin) as well
as the organ and tissue affinities of the drug relative to blood (i.e. tissue-blood partition
coefficients). With these physiologic parameters tissue blood flow roughly represents transfer
clearances between the central circulation and the tissue. The product of the tissue-blood
partition coefficient and tissue masses roughly equals the volume of distribution of the drug for
that tissue. Once the physiologic pharmacokinetic model is constructed, it is possible to simulate
the effect of changes in tissue blood flow or cardiac output on the time course of plasma drug
concentrations. Thus, physiologic models allow extrapolation outside the range of data and the
existing physiologic conditions as well as interspecies scaling if the mechanisms of transport are
understood and valid. A total body pharmacokinetic model describing generic drug disposition
in humans is given in figure 2 [5].
Figure 2. The total body pharmacokinetic model describing thiopental disposition in humans.
The model consists of multiple tissues and blood pools connected via the vasculature and assumes
venous injection and arterial blood sampling.
The inverse model is one of the most commonly de facto used in modern anesthetics and
drug delivery systems in general. Only drug concentrations vs time data is drawn from blood or
other tissue and fluids to create mathematical description (e.g. compartmental model), followed
by derivation or more often by correlation of model parameters with physiologic measurements.
This is the preferred method in humans as only time blood samples are needed for analyze
and regional blood flow measurements are not required. Moreover, continuous improvement in
drug measurement technology has made the acquisition of highly specific and sensitive drug
concentration data from small samples sizes relatively easy. Clearance refers to the process
of elimination of a substance from a volume. Distribution clearance describes the transfer of
the drug between blood or plasma and the peripheral tissues. Unlike metabolic clearance, in
distribution clearance the drug is not removed from the body. It is influenced by cardiac output,
tissue and organ blood flow, and capillary permeability of the drug. Some pharmacokinetic
parameters have precise physiologic meaning and can be used for estimates. Such progression
from pharmacokinetics to physiology is considered the inverse of the forward model of taking
physiologic principles and estimates to derive pharmacokinetics. Whichever way you look at it,
pharmacokinetics and physiology are interwoven. Compartmental models are augmented with
an extra effect-site compartment, to which corresponds an effect-site concentration [6, 7, 8]. The
plasma is not the site where the drugs unfold their clinical effects. This is usually the brain,
measured via EEG or evoked auditory potentials. Hence the main effect at the brain (effect
site) is delayed when compared to plasma peak concentration; this is represented by adding an
extra compartment (see figure 3).
The effect site is connected to the central compartment by a first order process, where the
constant K0e is the rate constant for elimination of drug from the effect site. This coefficient
has a large influence on the rate of rise and offset of drug effect, and the dose required to
Figure 3. The addition of an effect site to a three-compartment model refers to the fact that
the anesthetic effect takes place in the brain and not in the plasma. The effect site is calculated
as with a negligible volume..
produce a certain drug effect. The volume of the site effect is neglected. The model in figure 3
is represented by the following set of equations.
q˙1(t) = K21q2(t) +K31q3(t)−K12q1(t)−K13q1(t)−K01q1(t)−K1eq1(t) + U(t) (1)
q˙2(t) = K12q1(t)−K21q2(t)−K02q2(t) (2)
q˙3(t) = K13q1(t)−K31q3(t)−K03q3(t) (3)
q˙e(t) = K1eq1(t)−K0eqe(t) (4)
where: u - dosing scheme as a function of time; K01 - rate constant reflecting all processes
acting to irreversibly remove drug from the central compartment; K12, K13, K21, K31, K1e -
inter-compartmental rate constants [mg/l]; V 1 - volume of the central compartment [l], V2 and
V3 - volume of the peripheral compartments [l] ( respectively muscle and fat), q1 is the central
compartment (plasma), q2 is the rapidly equilibrium compartment (muscle), q3 is the slowly
equilibrium compartment (fat) and qe is the effect site compartment.
In daily clinical practice of general anesthesia, the goal is an individually tailored dosing of
drugs, resulting in the optimal anesthetic level that is neither too light nor too deep. On the one
side of the spectrum, excessively high drug doses (and inadequately deep levels of anesthesia)
should be avoided to reach short recovery times and prevent excessive depression of the
cardiovascular system. On the other side of the spectrum, inadequately low doses of anesthetics
(and inadequately light levels of anesthesia) must be avoided to guarantee unconsciousness and
prevent memory formation for intraoperative traumatic procedures (awareness). Under-dosage
of anesthetics leads to conscious perception or even awareness (conscious perception with explicit
memory) during anesthesia. Besides efforts to optimize anesthesia to shield the patient from
stress and consequences of surgery, cost saving and issues of economy may be an issue for
dosing strategies [9]. Management of anesthesia aimed at early recovery of the patient has
been addressed as so-called fast track anesthesia, which nevertheless comprises much more than
optimized dosing of anesthetic drugs. In this context, one challenge for the anesthesiologist
is to avoid both over- and under-dosage. Therefore, knowledge of the pharmacokinetic and
pharmacodynamic properties of anesthetic drugs is imperative.
The traditional form of target controlled dosing in anesthesia is by means of target controlled
infusion (TCI) [10] which was developed in the context of the development of the induction and
maintenance of general anesthesia by administration of intravenous agents only, i.e. the so called
total intravenous anesthesia (TIVA) [11]. From the above scheme it becomes evident that TCI
was the first formalized step that went beyond nave dosing and incorporated the dosing history
into the actual dosing scheme. Thereby pharmacokinetic-pharmacodynamic models were used
to estimate the present impact of doses given even far in the past on the present state of system.
The first device to realize the simultaneous administration of two drugs (hypnotic and opioid)
was named CATIA [12], computer-assisted titration of intravenous anesthesia. The name was
chosen to underline the importance of the computer, needed for:
• tracking when/which drug was given in what amount,
• for the calculation of how much drug will still reside in the volumes of distribution in the
body,
• what would be the future time course of dosing,
• maintaining a desired constant concentration in blood.
Newer developments take into account the hysteresis between blood and effect site and use the
concentration at the biophase as target [13]. Inherent to model-based dosing strategies is that
the model describes in general an average or typical patient. As the individual patient actually
treated on the basis of this model will deviate from the average, this will translate into prediction
errors with respect to the target concentrations. One approach to reduce systematic individual
deviations is to take into account the dependence of the PK parameters on anthropometric data
such as sex, age, weight, etc, by population pharmacokinetics [3], and to consider special patho-
physiological conditions of the patient or the specific anesthetic procedure and its co-medication
[14]. Another example where drug dosing represents a key role is the glucose-insulin system.
The glucose-insulin control is important since glucose represents the main energy source for the
brain. Low levels can affect the state of the patient (anxiety, aggressiveness, obfuscation, etc.)
coma and in some cases the death. On the other hand, high glucose levels produce vascular
and neural damages generating related diabetes complications (blindness, renal insufficiency,
ulceration, between others). The glucose insulin regulatory system can be described as two
coupled subsystems: the pancreatic system and the peripheral system. The inputs in the
pancreatic system are diverse stimuli (between them the glucose level is the most important)
and the output is the insulin liberated by the pancreas. In the peripheral system, the input
is the insulin and the output is the glucose level. This is, there is a coupling between them:
the output of one is the input for the other. The figure 4 shows the regulatory scheme. The
functional relation between the two subsystems can be quantified by the rate of change of the
glucose (G) and insulin (I) concentrations in time (t). The mathematical model can take the
form:
G˙(t) = f1(G, I, t); I(t) = f2(G, I, t) (5)
where: functions f1 and f2 are characteristics of each model. Based on these relation different
models have been proposed [15, 16]. A review of the mathematical modeling of glucose insulin
system can be found in [17].
For the specific case of diabetic patients, the drug dosing and monitor blocks in figure 1 refer
to the insulin doses and glucose monitoring respectively. The optimal route for insulin delivery
is the intravenous. However, this method presents important limitations and further research
has been oriented to subcutaneous pumps. Nowadays pumps technologies have become in an
accepted mode of insulin therapy. However, the subcutaneous insulin delivery presents a delay
between the insulin delivery and the subcutaneous absorption. This delay in general is not
constant and varies inter and intra patient.
One of the key issues of the control of the glucose is the estimation of the glucose levels.
An extended technique used to measure the glucose levels is Electrical Impedance Spectroscopy
(EIS). EIS is a tool that allows assessing the transfer function of a system based on an Alternate
Current (AC) input voltage and the resulting AC current response. From the transfer function
of the system different information regarding the behavior and structure of the system can be
derived. This technique requires an identification process that relates changes in the impedance
spectra with glucose changes in the biological system. An extended methodology to model those
changes is based on circuit analysis where the parameters of the circuit represent a specific
property in the system.
Different attempts to develop a glucose sensor based on this technique have been addressed.
However, enzyme stability (enzyme immobilization, critical operating sensor conditions such as
specific temperature and pH) increases the cost and limits the applications.
3. State of art
In an attempt to simplify the number of parameters in compartmental modeling, tools from
fractional calculus have been employed. The fractional calculus is a generalization of integration
and derivation to noninteger (fractional) order operators [15, 16]. First, a generalization of
the differential and integral operators into one fundamental operator Dnt (n the order of the
operation) which is known as fractional calculus. The reason why fractional calculus should be
implied in biological systems is the advantage given by the fact that it simplifies the dynamics
of complex and heterogeneous systems [7, 8]. In the model presented here we considered
the nonlinearity, consistency of units, mass balance and the fractional order rate constants.
Considering figure 3 represented by the following equations:
τn1−11 D
n1q1(t) = K21q2(t) +K31q3(t)−K12q1(t)−K13q1(t)−K1eq1(t)−K01q1(t) + U(t) (6)
τn2−12 D
n2q2(t) = K12q1(t)−K21q2(t)−K02q2(t) (7)
τn3−13 D
n3q3(t) = K13q1(t)−K31q3(t)−K03q3(t) (8)
τne−1e D
neqe(t) = K1eq1(t)−K0eqe(t) (9)
where: τ1, τ2, and τ3 represent the time elapsed for drug to diffuse from compartment 1,
respectively compartments 2 and 3. The introduction of leads to the dimensional homogeneity
of fractional rate equations, with the initial conditions q2(0) = d2 = 0, q3(0) = d3 = 0 and
q1(0) = d1 =bolus injection.
A numerical solution of the general fractional differential equation Dnt y(t) = f(y(t), t) can be
expressed as:
y(tk) = f(y(yk), tk)−
k∑
j=1
cnj y(tk−j) (10)
where: tk = kh, for k=1,2,3.N measured samples, h is the sampling period and c
n
j represent the
binomial coefficient which is calculated with the following expression:
cnj = (1−
1 + n
j
)cnj−1 (11)
Applying the general solution to the set of equations 6-9, we obtain the following fractional order
model describing drug diffusion in the body.
q1(tk) = (k21q2(tk) + k31q3(tk)− k12q1(tk)− k13q1(tk)− k01q1(tk − 1))hn −
k∑
j=1
cnj q1(tk−j) + u(t)
(12)
q2(tk) = (k12q1(tk))− k21q2(tk))hn −
k∑
j=i
cnj q2(tk−j) (13)
q3(tk) = (k13q1(tk))− k31q3(tk))hn −
k∑
j=i
cnj q3(tk−j) (14)
with: τn1−11 = τ
n2−1
2 = τ
n3−1
3 , k12 = K12/τ
n1−1
1 , k13 = K13/τ
n1−1
1 , k21 = K21/τ
n2−1
2 ,
k31 = K31/τ
n3−1
3 , k01 = K01/τ
n1−1
1 and assuming n1 = n2 = n3 = n for simplicity. Literature
reports upon several works dealing with such models [5, 6, 7, 17].
Another approach to physiologic and compartmental modeling is to use parsimonious models
which lose their link to physiology, but have the advantage of less number of parameters for
adaptation to the specific patient. There are several types of such models, based on both rational
and non-rational input-output relationship. For applications in anesthesia, parsimonious models
of rational functions have been published in [19] of the form:
G(s) =
b0 + b1s+ b2s+ . . . bnbs
nb
a1s+ a2s+ . . . anas
na
(15)
with non-rational orders [20].
For applications in diabetes general rational models in the Laplace domain allow reducing
the number of model parameters. However, fractional behavior of the impedance in biological
systems requires solutions that increase the flexibility of the models structure maintaining a
limited number of parameters [21]. For glucose sensors based EIS technique, fractional behavior
in the interface electrode-electrolyte has been identified. This interface can be modeled by a
structure with high number of resistors and capacitors. However, a constant phase element
(CPE) can be used to model this process [22]. The CPE is a fractional equivalent electrical
circuit and models an imperfect capacitor (the interface or double layer electrode electrolyte).
The impedance of the CPE is calculated by:
ZCPE =
1
Qoωα
e−j
pi
2
α (16)
with 0 < α < 1 , ω (rad/s) and Q0 an impedance element usually consisting of a capacitance
and resistance. Rational, parsimonious models use this element in order to reduce the number
of parameters while increasing the flexibility of the model [21, 22]. The generic goal of such
simplified models is to allow on-line identification of patients specificity by reducing the number
of model parameters. With such models at hand, adaptation of control target infusion levels
can be achieved as suggested for anesthesia in [23].
4. Perspectives
Current state of use in terms of TCI combined with feedback control in drug delivery systems is
still based on averaged population models. In anesthesia, several studies have been reported
successfully, making use of PID controllers [24, 25], nonlinear controllers [26], predictive
controllers [27, 28]. In closed loop control where the glucose changes are faster than insulin
absorption and action, the control algorithm should find a trade-off between slow-pace regulation
well suited to mild control actions applicable to quasi-state and postprandial regulations [29].
The well-known PID controller, given its reactive action, responds to glucose changes once
they occur, hence, it is necessary to develop a robust controller. However, a cautious design
could not produce an effective response to meal disturbances. The most modern controllers
are based on model predictive control algorithms using a model of the patient in order to
anticipate physiological actions [30, 31]. In glucose sensors based EIS, given the presence of
fractional behavior, general fractional models in the frequency domain can be proposed. In [32]
an approach using rational models in the Warburg variable (s) has been identified showing the
reduction of the parameters and clear identification of the glucose levels compared to integer
rational models. Further extension of fractional models identification in the frequency domain
can be found in [33]. The challenge for the next generation of drug delivery systems can be
summarized under two main trends:
• cyber-physical systems with integrated ICT platform for hybrid sources of information and
monitoring devices with the aim to deliver a decision making assist device;
• integrating parsimonious models into existing platforms of TCI and feedback control systems
for drug delivery systems.
The first trend involves the trans-disciplinary aspects of computer science, clinical expertise
and system engineering. It requires ingenuity of integrated systems, due to the hybrid nature
of various elements of such cyber-physical network. The second trend is based on system
engineering concepts (identification, control, stability and robustness). For non-rational patient
models, it requires moving away from the classical system theory approach. This might add
challenges for stability and robustness issues, which are critical for patient safety and well-being.
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